Meeting
2018 ASCO Annual Meeting
Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
Authors
Noa Biran
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
Noa Biran , David Samuel DiCapua Siegel , Jesus G. Berdeja , Noopur S. Raje , Robert F. Cornell , Melissa Alsina , Tibor Kovacsovics , Belle Fang , Amy Kimball , Carl Ola Landgren
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02335983
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8022)
DOI
10.1200/JCO.2018.36.15_suppl.8022
Abstract #
8022
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).
First Author: Ajai Chari
Poster
2015 ASCO Annual Meeting
Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
First Author: James R. Berenson
Poster
2014 ASCO Annual Meeting
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
First Author: David H. Vesole
Poster
2011 ASCO Annual Meeting
Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM).
First Author: J. Szymonifka